| Effect | Decrease |
| Trial Design | Double blind |
| Trial Length | 2-4 Weeks |
| Number of Subjects | 43 |
| Gender | Both Genders |
A pilot study in persons with mild to moderate (severe excluded) psoriasis (average age of 44, all caucasian), oral ingestion of 1g TTA for 28 days.Funding issues for this study:
Total cholesterol decreased 7.9%, triglycerides by 16.1%, and total fatty acids (serum) by 11.8%; the HDL to LDL ratio increased in favor of HDL, due to a decrease in non-HDL lipoproteins. IL-6, TNF-a, and VCAM-1 decreased for anti-inflammatory effects.
No adverse effects reported, although some parameters (bilirubin, alkaline phosphatase, GGT, leukocyte total) decreased nonsignificantly and within normal range with TTA.
Two researchers hold stock with the patent holder of TTA, minor but mentionable conflict of interest.
